NOTCH3 Overexpression

CI-VAR-00003185Explore in graph →CIViC 2578

Curated evidence

Evidence by cancer (2 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–2 of 2 evidence items across 2 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Malignant Pancreatic Neoplasm1
NOTCH3 Overexpression	Tarextumab	Predictive	D	Supports Sensitivity Response	3	submitted	EID7001 Notably, the antitumor efficacy of OMP-59R5 in combination with gemcitabine was significantly associated with expression of human Notch3 gene in pancreatic cancer. Tumors that were more sensitive to t… (full text at CIViC) PMID 25934888 · Yen et al., 2015 · Open in CIViC	civic
Rectal Carcinoma1
NOTCH3 Overexpression	Tarextumab	Predictive	D	Supports Sensitivity Response	3	submitted	EID7002 Finally, treatment of CRC cells with anti-Notch2/3 antibody increased Numb protein while significantly reducing formation of spheroids in both MICOL-14tum cells and primary tumor cultures. This novel … (full text at CIViC)

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.